Ivosidenib plus azacitidine significantly prolongs median overall survival in patients with IDH1-mutated acute myeloid leukemia (AML), with a median overall survival of 29.3 months versus 7.9 months ...
Long-term efficacy and safety results published in Blood Advances continue to demonstrate the sustained survival benefit of adding TIBSOVO to azacitidine in IDH1-mutated AML Data support the use of ...
Servier India, a subsidiary of the leading French pharmaceutical Servier Group, recently announced the launch of Ivosidenib (Tibsovo), an oral targeted therapy approved in the management of cancer ...
Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo), an oral targeted therapy ...
THE TRIBUNE, India’s oldest, daily English-language newspaper, was first published on February 2, 1881, in Lahore (now in Pakistan), and save for 40 days in the immediate aftermath of Partition, has ...
Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits Yearly Premium ₹999 ₹349/Year SUBSCRIBE NOW Yearly ...
"UPI now part of everyday life" : Finance Ministry as as July transactions hit 23 billion ...
First patient enrolled in the Phase 3 CHONQUER clinical trial in patients with IDH1-mutant conventional chondrosarcoma Phase 3 PyramIDH clinical trial in patients with IDH1-mutant myelodysplastic ...
HOUSTON -- Progression-free survival (PFS) in IDH-mutant low-grade glioma remained twice as high in adults who received vorasidenib (Voranigo) after surgery versus placebo, according to a follow-up ...
Alembic Pharmaceuticals Limited on Thursday announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for ...
Alembic has received tentative approval from the Food and Drug Administration for Ivosidenib Tablets, 250 mg, which is the generic of Servier’s Tibsovo. Ivosidenib is an isocitrate dehydrogenase-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results